Stock Monitor: Fate Therapeutics Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CTIC as the Company's latest news hit the wire. On March 09, 2018, the Company announced that results from the Phase-3 PERSIST-2 clinical trial assessing the efficacy and safety of pacritinib in patients with myelofibrosis and thrombocytopenia have been published online in JAMA Oncology. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Fate Therapeutics, Inc. (NASDAQ: FATE), which also belongs to the Healthcare sector as the Company CTI BioPharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, CTI BioPharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
The Phase-3 PERSIST-2 trial results were previously presented at the 58th American Society of Hematology (ASH) Annual Meeting, in December 2016.
Results of Phase-3 PERSIST-2 Clinical Trial
In the randomized, international, multicenter Phase-3 PERSIST-2 clinical trial, 149 patients were enrolled to evaluate pacritinib compared to best available therapy (BAT). The combined pacritinib arms of 400mg once daily and 200mg twice daily was administered.
18% of patients demonstrated 35% improvement in spleen volume reduction (SVR) at 24 weeks of treatment, compared 3% patients in the BAT arm, which included treatment with ruxolitinib. 25% of the patients demonstrated a greater than 50% reduction in total symptom score (TSS) compared to 14% patients in the BAT arm. Additionally, an exploratory analysis of the 74 patients who received pacritinib 200mg twice daily showed an improvement of 35% or more reduction of SVR in 22% patients and 50% or greater reduction of TSS in 32% patients.
On the safety front, the most common non-blood adverse events (AEs) were GI events, fatigue, peripheral edema, and dizziness. Diarrhea was the most frequently observed AE with pacritinib. Cardiac events in the treatment were reported at 32% versus 28% for BAT. Grade 3 or 4 cardiac events were reported in 13% patients treated with pacritinib once daily, 7% patients treated with pacritinib twice daily, and 9% patients treated with BAT.
CTI BioPharma Enrolling in Phase-2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia
The Company is currently enrolling patients in the PAC203 study, a Phase-2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. The study is evaluating the safety and efficacy of three dosing schedules, including 200mg twice daily (BID), 100mg twice daily (BID), and 100mg once daily (QD). The 200mg BID dose regimen was used in the Phase-3 PERSIST-2 trial of pacritinib in patients with myelofibrosis. The trial is expected to enroll up to approximately 105 patients.
Myelofibrosis is a relatively rare bone marrow cancer that disrupts the body's normal production of blood cells. The result is extensive scarring in bone marrow, leading to severe anemia, weakness, fatigue, and often an enlarged spleen. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders. Many people with myelofibrosis get progressively worse, and some may eventually develop a more serious form of leukemia.
Pacritinib, CTI BioPharma's lead product candidate, is an investigational oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: JAK2 and FLT3. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Activating mutations of JAK2 are implicated in certain blood-related cancers, including myeloproliferative neoplasms (MPNs), leukemia and certain solid tumors. FLT3 is a gene commonly found mutated in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2, and FLT3. inhibitors.
About CTI BioPharma Corp.
Founded in 1992 and headquartered in Seattle, Washington, CTI BioPharma is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
Stock Performance Snapshot
March 12, 2018 - At Monday's closing bell, CTI BioPharma's stock was slightly up 0.75%, ending the trading session at $4.04.
Volume traded for the day: 442.07 thousand shares, which was above the 3-month average volume of 412.92 thousand shares.
Stock performance in the last month – up 34.22%; previous three-month period – up 53.03%; past six-month period – up 25.08%; and year-to-date - up 50.75%
After yesterday's close, CTI BioPharma's market cap was at $172.67 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.